<\/p>\n
[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Description” tab_id=”1584624217032-a15849ed-97bb”][vc_column_text]CAPETAZ 500<\/strong>\u00a0tablets containing Capecitabine 500mg are Peach colored capsule shaped film coaed tablets. Capecitabine is a fluoropyrimidinecarbamate with antineoplastic activity. It is an orally administered systemic prodrug of 5\u2019-deoxy-5-fluorouridine (5\u2019DFUR) which is converted to 5-fluorouracil.<\/p>\n The chemical name for capecitabine is 5\u2019-deoxy-5-fluoro-N-[-(pentyloxy) carbonyl]-cytidine and has a molecular weight of 359.35. capecitabine has the following structural formula:<\/p>\n CLINICAL PHARMACOLOGY<\/strong><\/p>\n Capecitabine is relatively non-cytotoxic in vitro. This drug is enzymatically converted to 5 fluorouracil (5-FU)in vivo.<\/p>\n PHARMACOKINETICS<\/strong><\/p>\n In Colorectal Tumors and Adjacent Healthy Tissue<\/strong><\/p>\n Following oral administration of Capecitabine 7 days before surgery in patients with colorectal cancer, the median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range from 0.9 to 8.0). these ratios have not been evaluated in breast cancer patients or compared to 5-FU infusion.<\/p>\n Human Pharmacokinetics<\/strong><\/p>\n The pharmacokinetics of Capecitabine and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg\/m2\/day. Over this range, the pharmacokinetics of Capecitabine and did not change over time. The increases in the AUCs OF 5\u2019-dfur and 5-FU was greater than 85%.<\/p>\n Following oral administration of 825-mg\/m2capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 34% lower AUC for capecitabine than the Caucasian patients. The clinical significance of these differences is unknown. No signigicant differences occurred in the exposure to other metabolites (5\u2019DFCR, 5\u2019-DFUR, and 5-FU)<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Pharmacokinetics” tab_id=”1584624459062-96fb7e5b-0e23″][vc_column_text]<\/p>\n In Colorectal Tumors and Adjacent Healthy Tissue<\/strong><\/p>\n Following oral administration of Capecitabine 7 days before surgery in patients with colorectal cancer, the median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range from 0.9 to 8.0). these ratios have not been evaluated in breast cancer patients or compared to 5-FU infusion.<\/p>\n Human Pharmacokinetics<\/strong><\/p>\n The pharmacokinetics of Capecitabine and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg\/m2\/day. Over this range, the pharmacokinetics of Capecitabine and did not change over time. The increases in the AUCs OF 5\u2019-dfur and 5-FU was greater than 85%.<\/p>\n Following oral administration of 825-mg\/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 34% lower AUC for capecitabine than the Caucasian patients. The clinical significance of these differences is unknown. No signigicant differences occurred in the exposure to other metabolites (5\u2019DFCR, 5\u2019-DFUR, and 5-FU)<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Indications” tab_id=”1584624839401-59481bbb-bdc7″][vc_column_text]<\/p>\n Capecitabine is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated..<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Dosage & Administration” tab_id=”1584625017135-3ffdd9c5-1bd6″][vc_column_text]<\/p>\n The recommended dose of Capecitabine is 2500 mg \/m2 administered orally daily with food for 2weeks followed by a 1 week rest period given as 3 week cycles. The Capecitabine daily dose should be given orally in two divided doses (approximately 12 hours apart) at the end of a meal. Capecitabine tablets should be swallowed with water. The following table displays the total daily dose by body surface area and the number of tablets to be taken at each dose.<\/p>\n <\/p>\n *Total Daily dose divided by 2 to allow equal morning and evening doses.<\/p>\n Dose Modification guidelines:\u00a0<\/strong>Patients should be carefully monitored for toxicity. Toxicity due to Capecitabine administration may be managed by symptomatic treatment, dose interruptions and adjustment of Capecitabine dose. Once dose has been reduced it should not be increased at a later time.<\/p>\n <\/p>\n *National Cancer Institute of Canada Common Toxicity Criteria were used except for the Hand-and-Doot syndrome.<\/p>\n Adjustment of Starting Dose In Special Populations: Hepatic Impairment: In patient with mild to moderate hepatic dysfunction due to liver metastases, no starting dose adjustment tis necessary however, patients should be carefully monitored. Patients with severe hepatic dysfunction have not been studied.<\/p>\n Renal Important: Insufficient data are available in patients with renal impairment to provide a dosage recommendation.<\/p>\n Geriatric population: The elderly may be pharmcodynamically more sensitive to the toxic effects of 5-Fu and therefore, physician should exercise caution in monitoring the effects of Capecitabine in the elderly. Insufficient data are available to provide a dosage recommendation.<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Warnings” tab_id=”1587978979515-f8f30e91-41e3″][vc_column_text]<\/p>\n Coagulopathy:<\/strong>\u00a0Altered coagulation parameters and\/or bleeding have been reported in patients taking Capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.<\/p>\n Diarrhea:<\/strong>\u00a0Capecitabine can induce diarrhea, sometimes severe. Necrotizing enterocolitis has been reported with Capecitabine usage.<\/p>\n Pregnancy:<\/strong>\u00a0Capecitabine may cause fetal harm when given to a pregnant woman. If the drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Capecitabine.<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Precautions” tab_id=”1587978992501-6cfce856-3b3c”][vc_column_text]<\/p>\n A physician experienced in the use of cancer chemotherapeutic agents should monitor patients reciving therapy with Capecitabine. Most adverse events are reversible and do not need to result in discontinuation, although doses may need to be with held or reduced.<\/p>\n Hand-and-Foot Syndrome:<\/strong>\u00a0Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema) may occurs, administration of Capecitabine should be interrupted until the event resolve or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of Capecitabine should be decreased.<\/p>\n Cardiac:<\/strong>\u00a0There has been cardiotoxicity associated with fluorinatedpyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiograph changes. These adverse events may be more common in patients with a prior history of coronary artery disease.<\/p>\n Hepatic Insufficiency:<\/strong>\u00a0patients with mild to moderate hepatic dysfunction due to liver metastases should be carefully monitored when Capecitabine is administered. The effect of severe hepatic dysfunction on the disposition of Capecitabine is not known.<\/p>\n Hyperbilirubinemia:<\/strong>\u00a0If drug related grade 2-4 elevations in bilirubin occur, administration of Capecitabine should be immediately interrupted until the Hyperbilirubinemia resolves or decreases in intensity to grade 1.<\/p>\n Renal Insufficiency:<\/strong>\u00a0There is little experience in patients with renal impairment. Physicians should exercise caution when Capecitabine is administered.<\/p>\n Hematologic:<\/strong>\u00a0Capecitabine can lead neutropenia, thrombocytopenia and decreases in hemoglobin.<\/p>\n Carcinogenesis, Mutagenesis & Impairment of Fertility<\/p>\n Carcinogenesis and Mutagenesis:<\/strong>\u00a0Long \u2013 term studies in animals to evaluate the carcinogenic potential of Capecitabine have not been conducted. Capecitabine has not been shown to be mutagenic in vitro or in vivo.<\/p>\n Impairment of Fertility:<\/strong>\u00a0Capecitabine causes a decrease in fertility by disturbing the estrus. In male mice, Capecitabine causes degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids.<\/p>\n Nursing Women:<\/strong>\u00a0It is not known whether the drug is excreted in human milk. Because many durgs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants. It is recommended that nursing be discontinued when receiving Capecitabine therapy.<\/p>\n Pediatric Use:<\/strong>\u00a0The safety and effectiveness of Capecitabine in persons <18 years of age have not been established.<\/p>\n Geriatric Use: Patients >\/=80 years old may experience a greater incidence of gastrointestinal grade 4 or\u00a0 4 adverse events. Physicians should pay particular attention to monitoring the adverse effects of Capecitabine in the elderly.<\/p>\n Drug-Food Interaction: Since current safety and efficacy data are based upon administration of Capecitabine with food, it is recommended that Capecitabine be administered with food.<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Adverse Reactions (Side Effects)” tab_id=”1587979120358-05fb9d29-c798″][vc_column_text]<\/p>\n Adverse effects occurring in >\/5% of patients taking Capecitabine are as follows.<\/p>\n Gastrointestinal:\u00a0<\/strong>diarrhea, nausea, vomiting, stomatitis, abdominal pain, constipation and dyspepsia.<\/p>\n Skin and subcutaneous:<\/strong>\u00a0Hand-and-foot Syndrome, dermatitis and nail disorder.<\/p>\n General:<\/strong>\u00a0Fatigue, Pyrexia, pain in limb<\/p>\n Neurological:<\/strong>\u00a0Paresthesia, headache, dizziness and insomnia.<\/p>\n Metabolism:<\/strong>\u00a0Anorexia and dehydration<\/p>\n Eye:<\/strong>\u00a0Eye irritation<\/p>\n Musculoskeletal:\u00a0<\/strong>Myalgia<\/p>\n Cardiovascular:<\/strong>\u00a0Edema, Blood, neutropenia, thrombocytopenia, anemia, lymphopenia<\/p>\n Hepatobilliary:<\/strong>\u00a0Hyperbilirubinemia<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Drug Interactions” tab_id=”1587979189910-fa76cf3d-3ef0″][vc_column_text]Antacid:<\/strong>\u00a0Aluminum hydroxide and magnesium hydroxide containing antacid cause a small increase in plasma concentration of Capecitabine and one metabolite (5\u2019-DFCR).<\/p>\n Coumarin Anticoagulants:<\/strong>\u00a0Patients taking coumarinderivative anticoagulants concomitantly with Capecitabine should be monitored regularly for alterations in their coagulation parameters.<\/p>\n Phenytoin:<\/strong>\u00a0The level of phenytoin should be carefully monitored in patients taking Capecitabine and phenytoin dose may need to be reduced.<\/p>\n Leucovorin:<\/strong>\u00a0The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by Leucovorin.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Overdose & Contradiction” tab_id=”1587979235724-437f5588-0318″][vc_column_text]<\/p>\n The anticipated manifestations of acute overdose are nausea, vomiting, diarrhea, gastrointestinal irritation and bleeding and bone marrow depression. It should be managed with presenting clinical manifestations. Although no clinical experience has been reported dialysis may be of benefit in reducing circulating concentrations of 5-DFUR, a low molecular weight metabolite of the parent compound.<\/p>\n CONTRAINDICATIONS<\/strong><\/p>\n Capecitabine is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil.<\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Storage” tab_id=”1587979289759-3302c988-e641″][vc_column_text]<\/p>\n Store in a cool, dry place. Protect from light.<\/p>\n SHELF LIFE: 24months<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Presentation” tab_id=”1587979388259-cf07877f-c949″][vc_column_text]10 Strip of 10 Tablets.<\/p>\n HOW SUPPLIED<\/strong><\/p>\n Capetaz TM 500MG<\/strong><\/p>\n Capecitabine Tablets IP 500mg[\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":" Capecitabine Tab – 500MG<\/strong><\/p>\n Capecitabine is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated..<\/p>\n<\/div>\n<\/div>\n<\/div>\n![\"Capetaz\"](\"https:\/\/i0.wp.com\/www.zuviuslifesciences.in\/media\/34483\/capetaz-desc.jpg?ssl=1\")
[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Mechanism of Action \/ Pharmcodynamics” tab_id=”1584624217050-ebb8ae5e-43a6″][vc_column_text]<\/p>\n\n\n
\n Capecitabine Dose Calculation According to Body Surface Area<\/td>\n<\/tr>\n \n Dose level 225 mg\/m2\/day<\/td>\n Number of tablets to be taken at each dose (morning and evening)<\/td>\n<\/tr>\n \n Surface Area (m2)<\/td>\n Total Daily* Dose (mg)<\/td>\n 150 mg<\/td>\n 500mg<\/td>\n<\/tr>\n \n <\/= 1.24<\/td>\n 3000<\/td>\n 0<\/td>\n 3<\/td>\n<\/tr>\n \n 1.25-1.36<\/td>\n 3300<\/td>\n 1<\/td>\n 3<\/td>\n<\/tr>\n \n 1.37-1.51<\/td>\n 3600<\/td>\n 2<\/td>\n 3<\/td>\n<\/tr>\n \n 1.52-1.64<\/td>\n 4000<\/td>\n 0<\/td>\n 4<\/td>\n<\/tr>\n \n 1.65-1.76<\/td>\n 4300<\/td>\n 1<\/td>\n 4<\/td>\n<\/tr>\n \n 1.65-1.76<\/td>\n 4600<\/td>\n 2<\/td>\n 4<\/td>\n<\/tr>\n \n 1.92-2.04<\/td>\n 5000<\/td>\n 0<\/td>\n 5<\/td>\n<\/tr>\n \n 2.05-2.17<\/td>\n 5300<\/td>\n 1<\/td>\n 5<\/td>\n<\/tr>\n \n >\/=2.18<\/td>\n 5600<\/td>\n 2<\/td>\n 5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n\n
\n Recommended Dose Modifications<\/td>\n<\/tr>\n \n Toxicity NCCIC Grades*<\/td>\n During a Course of Therapy<\/td>\n Dose Adjustment for Next Cycle (% of starting dose)<\/td>\n<\/tr>\n \n Grade 1<\/strong><\/td>\n Maintain dose level<\/td>\n Maintain dose level<\/td>\n<\/tr>\n \n Grade 2<\/strong><\/td>\n<\/tr>\n \n 1st appearance<\/td>\n Interrupt until resolved to
\ngrade 0-1<\/td>\n100%<\/td>\n<\/tr>\n \n 2nd appearance<\/td>\n Interrupt until resolved to
\ngrade 0-1<\/td>\n75%<\/td>\n<\/tr>\n \n 3rd appearance<\/td>\n Interrupt until resolved to
\ngrade 0-1<\/td>\n50%<\/td>\n<\/tr>\n \n 4th appearance<\/td>\n Discontinue treatment
\npermanently<\/td>\n<\/td>\n<\/tr>\n \n Grade 3<\/strong><\/td>\n<\/tr>\n \n 1st appearance<\/td>\n Interrupt until resolved to
\ngrade 0-1<\/td>\n75%<\/td>\n<\/tr>\n \n 2nd appearance<\/td>\n Interrupt until resolved to
\ngrade 0-1<\/td>\n50%<\/td>\n<\/tr>\n \n 3rd appearance<\/td>\n Discontinue treatment
\npermanently<\/td>\n<\/td>\n<\/tr>\n \n Grade 4<\/strong><\/td>\n<\/tr>\n \n 1st appearance<\/td>\n Discontinue permanently or if physician deems it to be in the patient\u2019s best interest to continue, interrupt until resolved to grade 0-1<\/td>\n 50%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n